ARRY 520 trifluoroacetate
6 Inquiries
885060-09-3
0.98%
2026-06-25
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
ProductName ARRY 520 trifluoroacetate Cat No CEI-1218 Product Overview ARRY 520 trifluoroacetate is a synthetic and salt form of KSP inhibitor with IC50 value of 6 nM. Kinesin spindle protein (KSP) is one member of the mitotic kinesins involved in the early stages of mitosis responsible for centrosome separation. Clinical trial: A phase I trial was conducted to establish the safety and the maximum tolerated dose (MTD) of ARRY-520.The MTD was 4.5 mg/m2 total dose per cycle for both dose schedules. Dose-limiting toxicities included exfoliative rash, hand-foot-syndrome, mucositis, and hyperbilirubinemia. Grades 3 or 4 reversible drug-related myelosuppression were observed in 33 of 36 patients. CAS No 885060-09-3 Molecular Weight 420.48 Purity 0.98 Storage Store at -20°C Targets KSP Molecular Formula C20H22F2N4O2S. CF3CO2H Chemical Name (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide Solubility Soluble in DMSO > 10 mM Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request In vitro ARRY-520 had low nanomolar antiproliferative activity in various tumor cell lines and exhibited activity in multidrug-resistant cell lines. EC50s of ARRY-520 for proliferation inhibition in HCT-15, NCI/ADR-RES and K562/ADR cells was 3.7, 14 and 4.2 nM, respectively, while paclitaxel EC50s in these cell lines was 35, 565 and 372 nM. Moreover, K562/ADR was found to be 118-fold resistant to paclitaxel when compared to the parent K562 line, but only 3.5-fold resistant to that of ARRY-520. In vivo ARRY-520 was found to be active in UISO-BCA-1 xenografts, which were completely resistant to paclitaxel. The antitumor efficacy of ARRY-520 was also found to be superior to paclitaxel in mice bearing HT-29, HCT-116, MDA-MB-231 and A2780 xenografts. ARRY-520 was superior to docetaxel in the androgen receptor-negative prostate cancer PC-3 xenograft model, and was also superior to docetaxel in the DU145 prostate xenograft model. category Specialty Chemicals(c26) cas_num 885060-09-3 Basic Info-
Product Name:
Filanesib
Other Name:1,3,4-Thiadiazole-3(2H)-carboxamide,2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-,(2S)-;(2S)-2-(3-Aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide;Filanesib;ARRY 520;(2S)-2-(3-Aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide
CAS No.:885060-09-3
Molecular Formula:C20H22F2N4O2S
InChIKeys:InChIKey=LLXISKGBWFTGEI-FQEVSTJZSA-N
Molecular Weight:420.4760864
Exact Mass:420.48
UNII:8A49OSO368
DSSTox ID:DTXSID50237086
NCI Thesaurus Code:C68937
Categories:
Characteristics-
PSA:
96.5
XLogP3:3.27
Density:1.3±0.1 g/cm3
Boiling Point:511.3±60.0 °C at 760 mmHg
Flash Point:263.0±32.9 °C
Refractive Index:1.604
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Inquiry History6 Inquiries
Country Product Purchase Quantity Date Posted 
Pakistan
FINERENONE
700 KG Jul 13, 2023
Pakistan
FINERENONE
1 KG Aug 7, 2024
Pakistan
Finerenone
5 KG Apr 25, 2024 
India
Finerenone
50 KG Aug 1, 2023
Pakistan
Finerenone
5 KG Apr 26, 2024
Pakistan
FINERENONE
500 G Nov 20, 2023 Post an enquiry for this product